GSK / 葛兰素史克

GSK / 葛兰素史克 appears in 156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开 as a multinational pharma partner for [[HengruiPharma|恒瑞医药]]. The episode uses the deal as one example of the 2025 China innovation-drug BD surge.

The source’s point is structural: GSK is part of the MNC demand side created by patent cliffs, portfolio gaps, and the search for externally sourced pipelines. It is not presented as a full company case.

Connections

• Hengrui Pharma / 恒瑞医药 - Chinese partner named in the source.
• Multinational Pharma Patent-Cliff Anxiety - demand-side reason for large pharma BD.
• Global Pharma Commercialization - MNC operating capability context.